Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Soluble CD30 and CD23 in cord blood are not related to atopy in early childhood

Soluble CD30 and CD23 in cord blood are not related to atopy in early childhood Atopic disease, including atopic dermatitis (AD), is associated with a T‐helper 2 (Th2)‐dependent immune response. The cytokine receptor CD30 appears to be preferentially expressed on, and its soluble form (sCD30) released by, Th2 cells. Therefore, sCD30 may be a potential marker for atopic disorders. The aim of this study was to test the hypothesis that the sCD30 level in cord blood could be used to predict the development of atopy or AD in early childhood. In a case‐control study, levels of sCD30, as well as soluble low‐affinity immunoglobulin E (IgE) receptor (sCD23), interleukin‐4 (IL‐4) and IgE, were measured in cord blood in 35 children who subsequently developed allergic sensitization and AD before the age of three, and the results were compared to those of 35 matched children without a history of atopy. There was no difference in cord blood levels of sCD30 between controls (32.5 U/ml; 19.7–80.1) and children with subsequent atopy and AD (32.2 U/ml; 22–75.9) (median; quartiles). The concentration of sCD30 showed no relation to the levels of total IgE, sCD23 or IL‐4. Levels of sCD23 were similar in children with subsequent atopy (60.2 U/ml; 44.5–76.8) and controls (55.2 U/ml; 38.3–72.5), whereas IL‐4 was detectable in 10 of the atopic children and in only two of the controls (p < 0.05). In conclusion, cord blood levels of sCD30 or sCD23 do not seem to be related to the subsequent development of atopy or AD at the age of three. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatric Allergy and Immunology Wiley

Soluble CD30 and CD23 in cord blood are not related to atopy in early childhood

Download PDF
5 pages

Loading next page...
 
/lp/wiley/soluble-cd30-and-cd23-in-cord-blood-are-not-related-to-atopy-in-early-58ZUP80H2R

References (23)

Publisher
Wiley
Copyright
Copyright © 2000 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0905-6157
eISSN
1399-3038
DOI
10.1034/j.1399-3038.2000.00094.x
Publisher site
See Article on Publisher Site

Abstract

Atopic disease, including atopic dermatitis (AD), is associated with a T‐helper 2 (Th2)‐dependent immune response. The cytokine receptor CD30 appears to be preferentially expressed on, and its soluble form (sCD30) released by, Th2 cells. Therefore, sCD30 may be a potential marker for atopic disorders. The aim of this study was to test the hypothesis that the sCD30 level in cord blood could be used to predict the development of atopy or AD in early childhood. In a case‐control study, levels of sCD30, as well as soluble low‐affinity immunoglobulin E (IgE) receptor (sCD23), interleukin‐4 (IL‐4) and IgE, were measured in cord blood in 35 children who subsequently developed allergic sensitization and AD before the age of three, and the results were compared to those of 35 matched children without a history of atopy. There was no difference in cord blood levels of sCD30 between controls (32.5 U/ml; 19.7–80.1) and children with subsequent atopy and AD (32.2 U/ml; 22–75.9) (median; quartiles). The concentration of sCD30 showed no relation to the levels of total IgE, sCD23 or IL‐4. Levels of sCD23 were similar in children with subsequent atopy (60.2 U/ml; 44.5–76.8) and controls (55.2 U/ml; 38.3–72.5), whereas IL‐4 was detectable in 10 of the atopic children and in only two of the controls (p < 0.05). In conclusion, cord blood levels of sCD30 or sCD23 do not seem to be related to the subsequent development of atopy or AD at the age of three.

Journal

Pediatric Allergy and Immunology – Wiley

Published: Nov 1, 2000

There are no references for this article.